Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00228007
Status:
COMPLETED
Last Update Posted:
2013-08-22
First Post:
2005-09-26
Brief Title:
Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users
Sponsor:
Butler Hospital
Organization:
Butler Hospital
Study Overview
Official Title:
Maintaining HIV Risk Reduction Among Needle Exchangers
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the effectiveness of antidepressant medication treatment in reducing HIV risk behaviors in intravenous drug users with depression
Detailed Description:
Depression and injection drug use often come hand-in-hand This is especially true in populations with limited access to mental health care and with a high risk of illness and HIV transmission Depressed injection drug users in these populations usually continue their drug use for extended periods of time thereby further promoting the spread of HIV This cycle has created a significant public health problem It is necessary to explore new approaches to facilitate and maintain long-term behavior changes within this population This study will evaluate the effectiveness of treatment with antidepressant medications in reducing HIV risk behaviors in depressed intravenous drug users
Participants in this open label study will be randomly assigned to receive either antidepressant treatment or no treatment Participants in the treatment group will meet with a psychiatrist monthly for 12 months Based on psychiatric evaluations and participants medical histories doctors will prescribe an appropriate antidepressant medication or a combination of medications Participants in the treatment group may also receive referrals for other services if necessary Participants assigned to receive no treatment will be contacted at Months 3 and 9 to verify their contact information they will also receive any necessary referrals All participants will partake in interviews at baseline and Months 6 and 12 to assess changes in HIV risk behavior and depressive symptoms
Participants in this open label study will be randomly assigned to receive either antidepressant treatment or no treatment Participants in the treatment group will meet with a psychiatrist monthly for 12 months Based on psychiatric evaluations and participants medical histories doctors will prescribe an appropriate antidepressant medication or a combination of medications Participants in the treatment group may also receive referrals for other services if necessary Participants assigned to receive no treatment will be contacted at Months 3 and 9 to verify their contact information they will also receive any necessary referrals All participants will partake in interviews at baseline and Months 6 and 12 to assess changes in HIV risk behavior and depressive symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DAHBR AZ-Q | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH062719 |
| R01MH062719 | NIH | None | None |